The Association for Clinical Oncology (Association) is governed by a volunteer Board of Directors, which works to ensure that the Association achieves its mission and vision. Voting Board members are cancer physicians and clinical researchers who volunteer their time. View the Disclosures at the bottom of each individual’s bio. Please direct any questions related to Board members' disclosures to COI@asco.org.

Chair of the Association Board

Lori J. Pierce, MD, FASTRO, FASCO
View current ASCO disclosure here.

Dr. Pierce is a radiation oncologist, professor, and Vice Provost for Academic and Faculty Affairs at the University of Michigan. She is also director of the Michigan Radiation Oncology Quality Consortium. A national leader in breast cancer research, Dr. Pierce was previously a Senior Investigator at the National Cancer Institute, National Institutes of Health, and in 1992 joined the faculty at the University of Michigan where she has focused her career primarily on the treatment of breast cancer.

An active ASCO member since 1992, Dr. Pierce is a past member of multiple ASCO committees including the Government Relations Committee, Annual Meeting Scientific Program Committee and the Conquer Cancer Foundation Nominating Committee, and she served as a mentor for the Leadership Development Program from 2015 to 2018. She previously served on the ASCO Board of Directors from 2010 – 2014 and was named a Fellow of ASCO (FASCO) in 2015.

With over 180 manuscripts and book chapters published, Dr. Pierce has received numerous teaching and leadership awards including the American Association of Women Radiologists' Marie Curie Award and the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. In 2018, she was elected into the National Academy of Medicine. Most recently, Dr. Pierce was selected as the 2019 Woman of the Year by the United Way of Washtenaw County (UWWC) of Michigan.

Dr. Pierce completed her undergraduate degree in biomedical engineering at the University of Pennsylvania and her medical degree at Duke University. She completed her internship at the Thomas Jefferson University Hospital and her residency and chief residency in Radiation Oncology at the University of Pennsylvania.

Association Treasurer

Jason Westin, MD, MS, FACP
View current ASCO disclosure here.

Dr. Westin is the Director of the Lymphoma Clinical Research Program, the Director of the Lymphoma Planning Clinic and the Section Chief for Aggressive Lymphoma at the University of Texas MD Anderson Cancer Center in the Department of Lymphoma and Myeloma. His research interests include designing and conducting innovative clinical trials, CAR T-cell therapy, chemotherapy-free combinations, the development of new drugs and new methods to improve outcomes for patients with lymphoma. He is a graduate of the ASCO Leadership Development Program, and was previously awarded an ASCO CCF Young Investigator Award and ASCO CCF Career Development Award. He authored or co-authored more than 130 peer-reviewed original journal articles in oncology/hematology, including publications in the New England Journal of Medicine, Blood, The Lancet Oncology, and The Journal of Clinical Oncology.

Board Member

Ethan M. Basch, MD, MSc, FASCO
View current ASCO disclosure here.

Dr. Basch is chief of the division of oncology at the University of North Carolina and physician-in-chief of the North Carolina Cancer Hospital. He is the Richard M. Goldberg Distinguished Professor in Medical Oncology and professor of health policy & management. He serves as director of the cancer outcomes research program at UNC Lineberger Comprehensive Cancer Center, as associate editor at Journal of the American Medical Association, and on the editorial board of JCO Oncology Practice. He has previously served on the NCI Board of Scientific Advisors, on the Methodology Committee of PCORI, as chair of the ASCO Clinical Practice Guidelines Committee, the CancerLinQ Advisory Group, the Annual Meeting Education Committee, the Cancer Prevention Committee, and the Cancer Care Delivery Council.

Read Dr. Basch’s Q&A on ASCO Connection.

Board Member

Xylina T. Gregg, MD
View current ASCO disclosure here.

Dr. Gregg is a physician partner of Utah Cancer Specialists (UCS), Salt Lake City, Utah, and is Medical Director for UCS’ Laboratory and Imaging Services. She is the current President of the Society of Utah Medical Oncologists (SUMO). After completing a fellowship in Hematology Oncology at the University of Alabama at Birmingham (UAB), where she was a recipient of an American Society of Hematology (ASH) Travel Award, Dr. Gregg was an Assistant Professor at UAB and a member of the UAB Comprehensive Cancer Center. She subsequently joined Kelsey-Seybold Clinic, a multi-specialty clinic in Houston, Texas, where she was Hematology/Oncology Section Chief, Cancer Liaison Physician for the American College of Surgeons’ Commission on Cancer, and was a Clinical Assistant Professor at Baylor College of Medicine. Dr. Gregg has served on the ASH Committee on Practice, as the Utah Medicare Carrier Advisory Committee Hematology Representative, and as a Blood reviewer. She was Co-Chair of the National Community Oncology Dispensing Association (NCODA) Fall 2021 and Spring 2022 meetings. She has published in peer-reviewed journals and major Hematology texts, including multiple editions of Williams’ Hematology and Hematology: Basic Principles and Practice.

Board Member

Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO
View current ASCO disclosure here.

Dr. Mittendorf is the Rob and Karen Hale Distinguished Chair in Surgical Oncology at Brigham and Women’s Hospital, Associate Chair of Research for the Department of Surgery, and co-leader of the Breast Program at Dana-Farber / Harvard Cancer Center. She has previously served on ASCO’s Annual Meeting Scientific Program Committee and as chair of the Conquer Cancer Grants Selection Committee and chair of the ASCO-SITC Clinical Immuno-Oncology Symposium Scientific Program Committee. Dr. Mittendorf is currently the Treasurer of the Society Board of Directors.
 

Board Member

Elizabeth R. Plimack, MD, MS
View current ASCO disclosure here.

Dr. Plimack serves as the Deputy Director of Fox Chase Cancer Center in Philadelphia. She is a professor of medical oncology and the director of genitourinary clinical research at the center. She is a past member and track chair of the ASCO Scientific Program Committee, Genitourinary (Non-Prostate) Cancer track. She serves as a member of the Board’s Finance Committee and is the Board Liaison to the Cancer Communications Committee. Dr. Plimack received a Conquer Cancer Merit Award at the 2008 Genitourinary Cancers Symposium.

 Read Dr. Plimack's Q&A on ASCO Connection. 

Board Member

Lynn M. Schuchter, MD, FASCO
View current ASCO disclosure here.

Board Member

Michael A. Thompson, MD, PhD, FASCO
View current ASCO disclosure here.

Dr. Thompson is a medical oncologist and hematologist. He currently serves as the Vice President of Clinical Partnerships with Tempus Labs, Inc. He previously served as medical director for the Early Phase Cancer Research Program, co-PI of the Aurora NCORP as well as the co-director of Oncology Precision Medicine Program at Advocate Aurora Health. He currently maintains a hematology clinic at Aurora. He is a graduate of ASCO’s Leadership Development Program, has served as chair of the ASCO Annual Meeting Education Committee and the Research Community Forum Council, and is a current member of several ASCO volunteer groups. 

Read Dr. Thompson’s Q&A on ASCO Connection.

Board Member

Everett E. Vokes, MD, FASCO
View current ASCO disclosure here.

Dr. Vokes is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance (formerly Cancer and Leukemia Group B) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, a member of the Conquer Cancer Development and Fundraising Committee, and a member of the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009 to 2012.

Board Member

Eric P. Winer, MD, FASCO
View current ASCO disclosure here.  

Dr. Winer has been elected to serve as the ASCO President in 2022-2023. He is the Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven. Before then, he served as the chief clinical development officer, senior vice president for medical affairs, Director of the Dana-Farber/Harvard SPORE in Breast Cancer, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He has also served as a professor of medicine at Harvard Medical School. Dr. Winer served on the ASCO Board of Directors from 2011 to 2015 and has served as chair of the ASCO Government Relations Committee, Cancer Communications Committee, and Health Services Research Committee, among numerous volunteer roles. He was the recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School in 2020. He has also received numerous awards for his breast cancer research, most notably ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture in 2017 and the William L. McGuire Memorial Lecture Award in 2016 at the San Antonio Breast Cancer Symposium.

Non-Voting Board Member - Chief Executive Officer

Clifford A. Hudis, MD, FACP, FASCO
View current ASCO disclosure here.

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice-Chair of its Conquer Cancer Foundation and Chair of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s nearly 45,000 members.